Novo Nordisk Update | NVO
On December 22, 2025, the FDA approved Novo Nordisk's once-daily oral semaglutide (branded as the Wegovy pill), marking the first oral GLP-1 receptor agonist specifically for chronic weight management in…
Novo Nordisk Update | NVO
Novo Nordisk is an ethical drug development company operating out of Denmark. It is a company we think will perform well, with an undervalued stock. This article is for paid…
Novo Nordisk: NVO
On March 31, 2025, we suggested traders take a bullish position in NVO by selling a cash-covered put option on the stock. This article is for paid members - please…
Novo Nordisk: NVO
Diabetes is a chronic illness that seems to keep getting worse. Some people are born with it. However, we think the primary cause is diet. In particular, we point to…
Novo Nordisk: NVO
The ethical drug company Novo Nordisk will report earnings on Wednesday, January 31. Analysts expect the company to report EPS of $0.67 on revenue of $8.7 billion. This article is…